Francesco Lippi was born in Pisa (Italy) in 1951, September 2nd. Graduated in Medicine and Surgery at the University of Pisa (Medical Order in Pisa 1879/79). Specialization in Endocrinology and Metabolism at the University of Pisa July 1982 Specialization in Nuclear Medicine at the University of Florence July 1987 He has taught at the Institute of Clinical Methodology and Internal Medicine and at the Institute of Endocrinology and Metabolism of the University of Pisa (Italy). After Chernobyl accident partecipate to European Commision Study for diagnosis and treatment of children exposed to the radiations or radioactive follow-out (1990-1995). From 1990 Professor of Endocrinology at the University-Hospital of Pisa. He conducted as investigator in to the intenational study (phase III) on the effects of recombinant human TSH therapy (rhTSH, Thyrogen*) in compassionate use program in differentiated thyroid carcinoma with distant metastases. After that comparing a low activity vs high activty of radiodine therapy for treatment of thyroid remnants after surgery with rhTSH therapy without withdrawal of levotiroxine therapy. He held master's and refresher courses in Endocrinology and Nuclear Medicine at Stanford University (USA) (1997) for the treatment of thyroid carcinoma with rhTSH. He held an update master's degree at the Mayo Clinic in Rochester (USA). Associate of scientific associations in the field of Endocrinology. He partecipate to the study of ablation therapy using radiofrecency to reducethe volume of benign thyroid nodules. Actaually as Director of Thyroid Center Diseases in Pisa, University of Pisa (Italy).

He participated in the study on the efficacy of recombinant human TSH drug in differentiated thyroid carcinomas. He participate in the study on the efficacy of ethyl alcohol treatment in thyroid nodules. Studies the efficacy of radiofrequency treatment for the reduction of thyroid nodules with Tir1-Tir3A cytology.